lung tissue biopsies were cut into 1-mm 3 cubes and cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) newborn calf serum, penicillin (100 U/ml), streptomycin (100 μg/ml), and 2.5 μg/ml amphotericin B (all from Thermo Fisher Scientific). A near confluent monolayer of fibroblasts was obtained after 3 to 4 weeks and passaged. Experiments were conducted on cells between passages 3 and 13. Fibroblast cell line purify was confirmed by immunohistochemical characterization using antibodies to cytokeratin, von Willebrand factor, and desmin to rule out contamination by epithelial, mesothelial, endothelial, or smooth muscle cells.
All lines generated were negative for these markers and > 95% of cells stained positively for the mesenchymal marker, vimentin. Between 20 and 30% of cells were also positive for myofibroblast marker, α-smooth muscle actin. LFs were used between passage 3 and 13, maintained in DMEM at 37°C, 10% CO2, 100% humidity supplemented with L-glutamine, penicillin, streptomycin, fungizone, and 10% FBS (all from Thermo Fisher Scientific). For most experimental series LFs were seeded to become confluent within 24 hours prior to 24 hour serum starvation. The exception to this was for proliferation experiments where LFs were seeded at 7500 cells per well (96 well format), to allow a window for proliferation.
Primary human bronchial epithelial cell culture. Primary human bronchial epithelial cells (HBECs) were obtained from regions of normal airway of IPF or non-IPF control lung tissue as previously described 2 . HBECs were used at passage 3 and 4, maintained in BEGM (Lonza, Switzerland) at 37°C, 5% CO2, 100% humidity.
HBECs apoptosis. Sub-confluent HBECs were incubated for 72 hours in BEGM containing 10% FCS and 0.1% DMSO or increasing concentrations inhibitor. Preparation of precision cut lung slices. IPF lung tissue was inflated with 3% agarose (Sigma), 8mm cores prepared and 250μm slices generated using a Krumdieck tissue slicer and maintained overnight in DMEM at 37°C, 10% CO2, 100% humidity supplemented with L-glutamine, penicillin, streptomycin, fungizone, and 10% FBS (all from Invitrogen). For experiments, medium was replaced with fresh DMEM (0.4%FCS) with 0.1% DMSO or increasing concentrations inhibitor for 2 hours at 37°C. Lung slices were homogenized in ice cold PhosphoSafe buffer (Millipore) and assayed for pAkt using the Milliplex TGF signalling bead assay (Millipore; 48-614MAG), normalized to multiplexed GAPDH beads (Millipore; 46-667)."
In separate experiments supernatants were harvested for assessment of P1NP by proprietary competitive ELISA as previously described 3 .
Building a dose prediction model for GSK2126458 in IPF.
All in vitro data were first analyzed as a naïve pool using a non-linear mixed effects model 4 as a simulation of the inter-donor variability for fibroblast and BALF cell PD.
Using this approach, the cell assay data were described by the sigmoidal relationship described in Eqn. 1, Figure 5 (for output parameter estimates see Table   1 ). Next, predicted plasma concentration profiles for GSK2126458 in IPF patients were generated based on population PK data obtained from on-going oncology studies with GSK2126458 in patients with advanced solid tumours (http://www.gskclinicalstudyregister.com/study/112826#rs). The modelled PD and predicted PK data were combined in a stochastic simulation to predict target engagement in IPF patients at twice daily doses of 0.25, 1, 2 and 2.5 mg. Immunoreactivity for Akt phosphorylated at serine 473 (pAkt S473 , A) and threonine 308 (pAkt T308 , C) is shown in serial sections of discrete fibrotic foci, localizing to spindle shaped cells immuno-reactive for SMA (white asterisk, E), as well as capillary endothelium. Immuno-staining for both phosphorylation sites was also observed in epithelial cells overlying the fibrotic focus (pAktS473 A and pAktT308 C, black asterisk E). Signal for pAktS473 and pAktT308 was present in bronchial epithelium (B, D respectively), and macrophages delineated by CD68 (Arrow, G; pAktS473, A; pAktT308,C), with poor signal pAkt signal observed in SMA positive airway smooth muscle (F, pAktS473, B; pAktT308,D) ; scale bar, 150μm. The fibrotic focus is also shown at high power, scale bar 50μm (inset) Negative immuno-staining with non-immune IgG at equivalent dilutions to pAkt S473 and pAkt T308 specific antibodies also shown (H and I). Figure S3 . Induction of Apoptosis in crowded cell culture. Activation of fibroblast caspase 3 and 7 was assessed in confluent crowded culture conditions following TGF stimulation and treatment with increasing concentrations of GSK2126458. Data from n=5 C-LF lines are shown and data expressed fold relative to baseline without TGF (0.1%DMSO) (Veh) and shown as mean +/-SEM for n=4 replicate wells per condition; ** P<0.0001 for differences in raw values from no vehicle controls (2 way ANOVA, Tukey's multiple comparisons test).
Compound 1 GSK2126458 pIC50 n (total) Comments pIC50 n (total) Comments PI3K-alpha 10.4 3 2 values of > 9.9 9.5 10 2 values of > 10.0 PI3K-beta 9.5 3 1 value of > 9.9 9.1 10 PI3K-delta 10.6 3 2 values of > 9.6 9.3 10 5 values of > 9.58 PI3K-gamma 9.9 2 1 value of > 9.4 9.3 10 FRAP1 9.5 1 9.6 1 Table S1 . pIC50 for PI3K/ mTOR inhibitors in recombinant assays (GSK). pIC50 in recombinant assays (GlaxoSmithKline, Upper Merion, PA). Data points below the concentration limit of the assay are excluded from the summary mean in the PI3K isoform data. An overview of the data is provided in the table. The pIC50 quoted is the mean for the non-modified values; the n is the total of instances the compound has been assayed and the comment field illustrates the instances when the compound tested beyond the limit of the assay. Table S6 : Summary pharmacology of the effect of GSK2126458 on BAL cell pAkt
